Market Place
Sourcing Support
Indaptus Secures $6M Investment From Investor David E. Lazar
29 Dec 2025 //
GLOBENEWSWIRE
Indaptus Therapeutics Reveals Q3 2025 Financials & Corporate
12 Nov 2025 //
GLOBENEWSWIRE
Indaptus Therapeutics Provides Clinical Update
04 Sep 2025 //
GLOBENEWSWIRE
Indaptus Therapeutics Q2 2025 Results and Corporate Update
13 Aug 2025 //
GLOBENEWSWIRE
Indaptus Therapeutics Sells $2.3M in Private Placement
13 Jun 2025 //
GLOBENEWSWIRE
Indaptus Therapeutics Doses First Patient in Decoy20 Study
02 Jun 2025 //
GLOBENEWSWIRE
Indaptus Therapeutics Q1 2025 Financial Results & Update
14 May 2025 //
GLOBENEWSWIRE
Indaptus Founder Dr. Michael Named Chair & Expert Speaker
08 May 2025 //
GLOBENEWSWIRE
Indaptus Therapeutics CMO Roger Waltzman to Moderate CMO360 Summit
25 Mar 2025 //
GLOBENEWSWIRE
Indaptus Therapeutics Reports Successful Immune Activation in Dec
20 Mar 2025 //
GLOBENEWSWIRE
Indaptus Therapeutics Initiates Phase 1 Combination Study
18 Mar 2025 //
GLOBENEWSWIRE
Tribe Public Webinar With Indaptus Therapeutics
12 Mar 2025 //
GLOBENEWSWIRE
Indaptus Expands Patent Portfolio In China, Japan, And Israel
04 Mar 2025 //
GLOBENEWSWIRE
Indaptus Therapeutics Receives in Canada Approval for Decoy20 Trial
05 Feb 2025 //
GLOBENEWSWIRE
Indaptus Therapeutics Announce 2.25M Private Placement Under Nasdaq
13 Jan 2025 //
GLOBENEWSWIRE
Indaptus Therapeutics Provides Year-End Review & Outlook for 2025
08 Jan 2025 //
GLOBENEWSWIRE
Indaptus Therapeutics Announces $2.135M Registered Offering
22 Nov 2024 //
GLOBENEWSWIRE
Indaptus Therapeutics Reports Q3 2024 Financial Results & Update
12 Nov 2024 //
GLOBENEWSWIRE
Indaptus Therapeutics Publishes Immunotherapy Research in Immunology
11 Nov 2024 //
GLOBENEWSWIRE
Indaptus Presents Safety Data from Decoy20 Phase 1 at SITC 2024
07 Nov 2024 //
GLOBENEWSWIRE
Indaptus Signs Clinical Supply Agreement With BeiGene
22 Oct 2024 //
GLOBENEWSWIRE
Indaptus Initiates Unrestricted Enrollment Of Decoy20 Weekly Dosing
15 Oct 2024 //
GLOBENEWSWIRE
Indaptus Founder To Speak On Cancer Immunotherapy Webinar
10 Oct 2024 //
GLOBENEWSWIRE
Indaptus Reports New Safety Data For Decoy20 Program
05 Sep 2024 //
GLOBENEWSWIRE
Indaptus Reports Q2 2024 Results And Provides Corporate Update
12 Aug 2024 //
GLOBENEWSWIRE
Indaptus Therapeutics Announces $3.0M Registered Direct Offering And Placement
07 Aug 2024 //
GLOBENEWSWIRE
Indaptus to Present at the MedInvest Biotech and Pharma Investor Conference
28 Mar 2024 //
GLOBENEWSWIRE
